Open Access Open Badges Research article

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease

Aaron H Burstein1*, Imogene Grimes1, Douglas R Galasko2, Paul S Aisen2, Marwan Sabbagh34 and Adnan MM Mjalli1

Author Affiliations

1 TransTech Pharma, High Point, NC, USA

2 Department of Neurosciences, University of California, San Diego, CA, USA

3 Banner Sun Health Research Institute, Sun City, AZ, USA

4 University of Arizona, Tucson, Arizona, AZ, USA

For all author emails, please log on.

BMC Neurology 2014, 14:12  doi:10.1186/1471-2377-14-12

Published: 15 January 2014



TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488. Acute, reversible cognitive worsening was seen with a 20 mg/day dose. The present study further evaluates the efficacy of TTP488 by subgroup analyses based on disease severity and concentration effect analysis.


399 patients were randomized to one of two oral TTP488 doses (60 mg for 6 days followed by 20 mg/day; 15 mg for 6 days followed by 5 mg/day) or placebo for 18 months. Pre-specified primary analysis, using an ITT population, was on the ADAS-cog11. Secondary analyses included as a key secondary variable the Clinical Dementia Rating-Sum of Boxes (CDR-SB), and another secondary variable of the ADCS-ADL.


On-treatment analysis demonstrated numerical differences favoring 5 mg/day over placebo, with nominal significance at Month 18 (delta = 2.7, p = 0.03). Patients with mild AD, whether defined by MMSE or ADAS-cog, demonstrated significant differences favoring 5 mg/day on ADAS-cog and trends on CDR-sb and ADCS-ADL at Month 18. TTP488 plasma concentrations of 7.6-16.8 ng/mL were associated with a decreased decline in ADAS-cog over time compared to placebo. Worsening on the ADAS-cog relative to placebo was evident at 46.8-167.0 ng/mL.


Results of these analyses support further investigation of 5 mg/day in future Phase 3 trials in patients with mild AD.